Microbiologic factors affecting Clostridium difficile recurrence

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012  M. Tvede,
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods  A. Ducournau, L. Bénéjat, E. Sifré, E. Bessède,
J.-C. Lagier  Clinical Microbiology and Infection 
L. Boyanova  Clinical Microbiology and Infection 
The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection  R. Singh, M. Nieuwdorp, I.J.M.
Gut bacterial microbiota and obesity
I.J. Schalk  Clinical Microbiology and Infection 
Approach to diagnosis of infective endocarditis
E. Charani, C. Tarrant, K. Moorthy, N. Sevdalis, L. Brennan, A. H
D. Khalil, M. Hultin, M.U. Rashid, B. Lund 
Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis  J.
Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis  T. Steinmetz, N.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection.
Migrant health—a cause for concern?
Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics  Y.H. van Beurden, S. Nezami,
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
David L. McCollum, J. Martin Rodriguez 
Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance—a retrospective population based study.
Discrepancies between general practitioners' vaccination recommendations for their patients and practices for their children  N. Agrinier, M. Le Maréchal,
Whole genome analysis of Mycobacterium tuberculosis isolates from recurrent episodes of tuberculosis, Finland, 1995–2013  V. Korhonen, P.W. Smit, M. Haanperä,
R. Cantón  Clinical Microbiology and Infection 
A.E. Muller, U. Theuretzbacher, J.W. Mouton 
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
E. Bouza  Clinical Microbiology and Infection 
Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013  L.E.B. Nabarro, R.A. Lever, M. Armstrong,
Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?  T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt 
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection  Sarah M. Bartsch, Craig A. Umscheid,
Impact of antibiotic restrictions: the pharmaceutical perspective
Vector control: a cornerstone in the malaria elimination campaign
Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients 
Sofie Arens, Jan Verhaegen, Ludo Verbist 
Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients  S. Erb, R. Frei,
Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients.
G. Höffken  Clinical Microbiology and Infection 
C. Fabrizio, A. Procopio  Clinical Microbiology and Infection 
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study  E. Manea, J. Sojo-Dorado, R.E. Jipa, S.N.
Levofloxacin in the treatment of ventilator-associated pneumonia
R. Bitterman, M. Paul, D. Polak, Y. Geffen 
Mathematical modeling of Clostridium difficile infection
Metagenomics and probiotics
Previously unknown species of Aspergillus
Laboratory diagnosis of Clostridium difficile disease
The economic burden of Clostridium difficile
J. Garau  Clinical Microbiology and Infection 
Sexually acquired Zika virus: a systematic review
Systematic review of antibiotic consumption in acute care hospitals
Pandemic lineages of extraintestinal pathogenic Escherichia coli
N. Jazmati, M. Hellmich, B. Ličanin, G. Plum, A.J. Kaasch 
Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about.
Current experience in treating invasive zygomycosis with posaconazole
R. U. Varier, E. Biltaji, K. J. Smith, M. S. Roberts, M. K. Jensen, J
Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013  U. Fedeli, E. Schievano,
Statin use and clinical outcomes among pneumonia patients
Clinical Microbiology and Infection
C.P. Kelly  Clinical Microbiology and Infection 
J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin 
Virology: a scientific discipline facing new challenges
R. Khatib, G. Simeunovic, M. Sharma, M. G. Fakih, L. B. Johnson, L
First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Typing of Clostridium difficile
Impact of antibiotic restrictions: the patient's perspective
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection  A. Russo, M. Falcone, M. Fantoni, R. Murri,
Presentation transcript:

Microbiologic factors affecting Clostridium difficile recurrence C.H. Chilton, D.S. Pickering, J. Freeman  Clinical Microbiology and Infection  Volume 24, Issue 5, Pages 476-482 (May 2018) DOI: 10.1016/j.cmi.2017.11.017 Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 The Microbiological factors affecting C. difficile infection and recurrence. 1. The Microbiota - A ‘healthy’ microbiota is refractive to C. difficile spore colonisation, but once microbiota populations are disrupted (e.g. by antibiotic exposure), C. difficile infection (CDI) can occur. Antibiotic treatment of CDI can resolve the infection, but can maintain the microbiota in a disrupted state, leaving a patient susceptible to recurrence of CDI. This can lead to a vicious cycle of recurrent disease. 2. C. difficile spore viability - A disrupted microbiota will not lead to CDI (or recurrent CDI) unless C. difficile spores are present in the gut. These spores must germinate, proliferate and release toxin for a symptomatic recurrent episode to occur. Clinical Microbiology and Infection 2018 24, 476-482DOI: (10.1016/j.cmi.2017.11.017) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions